Pfizer Selzentry Will Launch At $29/Day; sNDA For Full Approval Slated For August
Executive Summary
Pfizer's HIV therapy Selzentry (maraviroc) will be available in pharmacies by mid-September following FDA's Aug. 6 approval of the first-in-class CCR5 co-receptor antagonist
You may also be interested in...
Reanalyzed MERIT Data Suggests Selzentry Efficacy Matches HIV Standard Of Care
Enhanced Trofile assay reveals previous data included patients with HIV variants who should have been excluded, Pfizer and Monogram Biosciences report at ICAAC.
AIDS Drug Rebates Were “Largest Driver” Of ADAP Budget Growth In 2007
Manufacturer rebates on AIDS drugs now account for 18 percent of the overall budget for AIDS Drug Assistance Programs, compared to 6 percent in the mid-1990s, according to the National ADAP Monitoring Project's annual report, released April 8
AIDS Drug Rebates Were “Largest Driver” Of ADAP Budget Growth In 2007
Manufacturer rebates on AIDS drugs now account for 18 percent of the overall budget for AIDS Drug Assistance Programs, compared to 6 percent in the mid-1990s, according to the National ADAP Monitoring Project's annual report, released April 8